¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"risk ratio"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • risk benefit analysis
    À§ÇèÆíÀͺм®
  • risk difference
    À§ÇèµµÂ÷ÀÌ
  • risk factor
    À§ÇèÀÎÀÚ
  • risk management
    À§Çèµµ°ü¸®
  • risk marker
    À§ÇèÇ¥ÁöÀÚ
  • arm ratio
    µÎÆÈºñ
  • axial ratio
    Ãàºñ
  • abortion ratio
    À¯»êºñ
  • age-dependency ratio
    ¿¬·ÉºÎ¾çºñ
  • air entrainment ratio
    °ø±âÀ¯ÀÔ·ü
  • air pollution ratio
    ´ë±â¿À¿°·ü
  • albumin CSF/serum ratio
    ¾ËºÎ¹Î³úô¼ö¾×/Ç÷ûºñ
  • albumin-globulin ratio
    ¾ËºÎ¹Î±Û·ÎºÒ¸°ºñ
  • birth-death ratio
    Ãâ»ý»ç¸Áºñ
  • blood urea nitrogen/creatinine ratio
    Ç÷¾×¿ä¼ÒÁú¼Ò/Å©·¹¾ÆÆ¼´Ñºñ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • uptake ratio
    ¼·ÃëÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high risk group
    °íÀ§Çèµµ±º
  • lifetime risk
    Æò»ýÀ§Çèµµ
  • multiple risk
    ´ÙÁßÀ§Çèµµ
  • risk management
    À§Çèµµ°ü¸®
  • risk marker
    À§Ç赵ǥÁö
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸»ó´ëÀ§Çè¸ðµ¨
  • operative risk
    ¼ö¼úÀ§Çèµµ
  • physical hazard risk
    ¹°¸®ÀûÀ¯ÇØÀ§Çèµµ
  • population attributable risk
    ÀϹÝÀα¸±â¿©À§Çèµµ
  • risk
    À§Çè, À§Çèµµ
  • radiation risk
    ¹æ»ç¼±À§Çèµµ
  • recurrence risk
    Àç¹ßÀ§Çèµµ
  • relative risk
    ºñ±³À§Çèµµ
  • surgical risk
    ¼ö¼úÀ§Çèµµ
  • A-G ratio
    (¢¡albumin-globulin ratio) ¾ËºÎ¹Î±Û·ÎºÒ¸°ºñ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative risk
    ºñ±³À§Çèµµ
  • relative risk estimation
    »ó´ë(-Àû) À§Çèµµ ÃßÁ¤(õÏïÒ)
  • DeRitis ratio
    µå¸®Æ¼½ººñÀ²
  • Donnan ratio
    µ·³­À²
  • G/N ratio
    G/Nºñ Æ÷µµ´ç°ú Áú¼ÒÀÇ ºñÀ² .
  • INR => International Normalized Ratio
    ±¹Á¦Á¤»óÈ­ºñÀ²
  • International Normalized Ratio
    ±¹Á¦Á¤»óÈ­ºñÀ²
  • International Normalized Ratio=INR
    ±¹Á¦Á¤»óÈ­ºñ
  • L/S ratio
    L/S ºñÀ²
  • OER [=oxygen enhancement ratio]
    »ê¼Ò°­È­À²
  • S-D ratio
    ¼öÃà±â-À̿ϱ⠺ñ (â¥õêÑ¢-ì¬èÐÑ¢ Ýï)
  • SNR (signal to noise ratio)
    ½ÅÈ£´ë ÀâÀ½ºñÀ²
  • V/Q => ventilation/perfusion ratio
    ȯ±â/°ü·ùºñ
  • VA/Q => ventilation/perfusion ratio
    ȯ±â/°ü·ù ºñ
  • air entrainment ratio
    °ø±âÀ¯ÀÔ·ü.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • radiation risk
    ¹æ»ç¼±À§ÇØ, ¹æ»ç¼± À§Çè
  • radiation risk coeffecient
    ¹æ»ç¼±À§ÇèÁö¼ö
  • recurrence risk
    Àç¹ßÀ§Çè
  • relative risk
    ºñ±³À§Çèµµ
  • relative risk
    ºñ±³À§Çèµµ(ËÓË´Ëô̴̬).
  • relative risk estimation
    »ó´ë(-Àû) À§Çèµµ ÃßÁ¤(õÏïÒ)
  • risk factor
    À§ÇèÀÎÀÚ
  • risk factors
  • risk management
    À§Çè°ü¸®.
  • risk-benefit analysis
    À§Çè-À̵æºÐ¼®
  • surgical risk
    ¼ö¼úÀ§Çèµµ(¼ö¼úÀ§ÇèŹ).
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸¼º »ó´ëÀ§Çè¸ðµ¨
  • air entrainment ratio
    °ø±âÀ¯ÀÔ·ü.
  • air pollution ratio
    ´ë±â¿À¿°·ü(ÊÙËô).
  • albumin CSF/serum ratio
    ¾ËºÎ¹Î ³úô¼ö¾×/Ç÷û ºñ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Donnan ratio
    µ·³­ À²(ëÒ)
  • extraction ratio
    ÃßÃâºñ(õÎõóÝï)
  • flux ratio method
    Çöô½º ºñÀ²¹ý(Ýï×ËÛö)
  • frictional ratio
    ¸¶Âûºñ(ؤóÍÝï)
  • G + C/A + T ratio
    G + C/A + T ºñ(Ýï)
  • gyromagnetic ratio
    ÀÚ±âȸÀü ºñ(í¸Ñ¨üÞï®Ýï)
  • ratio
    ºñÀ²(Ýï×Ë)
  • induction ratio
    À¯µµºñ(ë¯ÓôÝï)
  • inhibition ratio
    ÀúÇØÀ²(îÁúªëÒ)
  • L/S ratio
    L/S À²(ëÏ)
  • mass-action ratio
    Áú·®ÀÛ¿ëÀ²(òõÕáíÂéÄëÒ)
  • nucleo-cytoplasmic ratio
    ÇÙ(ú·).¼¼Æ÷Áú(á¬øàòõ) ºñ(Ýï)
  • packing ratio
    ÆäÅ·À²(ëÒ)
  • polarity ratio
    ±Ø¼º ºñÀ²(пàõÝï×Ë)
  • P:O ratio
    P/O ºñ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • velocity ratio
    ¼Óµµºñ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
A/G ratio Albumin/Globulin ratio; ¾ËºÎ¹Î´ë ±Û·ÎºÒ¸°ÀÇ ºñÀ²
S/D ratio Systolic / Diastolic ratio
C/N carbon/nitrogen [ratio]; carrier/ noise [ratio]
DR degeneration reaction; delivery room; deoxyribose; diabetic retinopathy; diagnostic radiology; digit...
ER efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AR At-Risk
ARIC Atherosclerosis Risk In Communities
AR Attributable Risk
BRFSS Behavioral Risk Factor Surveillance System
CVRF Cardiovascular risk factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • child woman ratio
    ¸ð¾Æ ºñÀ²
  • crown-root ratio
    Ä¡°ü´ë Ä¡±Ùºñ
  • curative ratio
    Ä¡À¯À²
  • death ratio
    »ç¸Áºñ
    µ¿ÀǾî=
  • effective ratio
    À¯È¿À²
    ¾î´À ÇѰè±îÁö´Â ¾àÁ¦ ¿ë·®°ú À¯È¿À²Àº ºñ·ÊÇÑ´Ù. ÇѰè À̻󿡼­´Â ºÎÀÛ¿ëÀÌ ³ªÅ¸³­´Ù.
  • expansion ratio
    ÆØÃ¢ºñ
  • innervation ratio
    ½Å°æ Áö¹è ºñ
  • magnetization transfer ratio
    ÀÚÈ­ Àü´Þ ºñÀ²
  • mercuryalloy ratio
    ¼öÀº Çձݺñ
  • monocyte lymphocyte ratio
    ´Ü±¸ ¸²ÇÁ±¸ºñ
  • optimal ratio
    ÃÖÀûºñ
  • optimum ratio
    ÃÖÀûºñ
  • phase ratio
    »óºñ
  • ratio
    ºñ
    ¾î¶² ¹°Áú ¶Ç´Â ½ÇüÀÇ ¾çÀ» ´Ù¸¥ °Í°ú ºñ±³ÇÑ Ç¥ÇöÀ¸·Î¼­, º¸Åë ÇÑÂÊÀÇ ¾çÀ» ´Ù¸¥ÂÊÀÇ ¾çÀ¸·Î ³ª´« °ªÀ¸·Î Ç¥½ÃÇÑ´Ù.
  • sex ratio
    ¼ººñ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
risk reduction Techniques used to reduce your chances of getting a certain cancer. For example: reducing your dietary fat may help prevent breast cancer.
(09 Oct 1997)
risk-taking Undertaking a task involving a challenge for achievement or a desirable goal in which there is a lack of certainty or a fear of failure. It may also include the exhibiting of certain behaviours whose outcomes may present a risk to the individual or to those associated with him or her.
(12 Dec 1998)
competing risk An event that removes a subject from being at risk for an outcome under investigation.
(05 Mar 2000)
pregnancy, high-risk Pregnancy in which the mother and/or foetus are at greater than normal risk of morbidity or mortality. Causes include lack of adequate prenatal care, previous obstetrical history, pre-existing maternal disease or pregnancy-induced disease, and multiple gestation, as well as advanced maternal age.
(12 Dec 1998)
health risk assessment Method of describing an individual's chance of falling ill or dying of a specified condition, based on actuarial calculations that allow for known exposure to risk; expressed as expected age at which death or disease will occur, and intended as a way of drawing an individual's attention to the probable consequences of risk behaviour.
(05 Mar 2000)
oesophageal carcinoma risk factors <radiology> P Plummer-Vinson Web, A achalasia, alcohol, B Barrett oesophagus, S stricture, T tylosis, tobacco see: oesophageal carcinoma
(12 Dec 1998)
thyroid carcinoma risk factors <radiology> Increased risk of malignancy: young female, male, history of radiation to head or neck, hard lesion, other neck masses, no shrinkage on TSH, family hx of thyroid carcinoma see: thyroid carcinoma
(12 Dec 1998)
empiric risk The chance that a disease will occur in a family based upon experience (past history, medical records, etc.) rather than theory.
(12 Dec 1998)
absolute terminal innervation ratio The number of motor endplates divided by the number of terminal axons related to them.
(05 Mar 2000)
accommodative convergence-accommodation ratio The amount of convergence (measured in prism diopters of convergence) divided by the amount of accommodation (measured in diopters) required to direct both eyes upon an object.
(05 Mar 2000)
A/G ratio <abbreviation> Albumin-globulin ratio.
(05 Mar 2000)
albumin-globulin ratio The ratio of albumin to globulin in the serum or in the urine in kidney disease; the normal ratio in the serum is approximately 1.55.
(05 Mar 2000)
ALT:AST ratio The ratio of serum alanine aminotransferase to serum aspartate aminotransferase; elevated serum levels of both enzymes characterise hepatic disease; when both levels are abnormally elevated and the ALT:AST ratio is greater than 1.0, severe hepatic necrosis or alcoholic hepatic disease is likely; when the ratio is less than 1.0, an acute non-alcoholic hepatic condition is favoured.
(05 Mar 2000)
amylase-creatinine clearance ratio A test for the diagnosis of acute pancreatitis; it is determined by measuring amylase and creatinine in serum and urine in apparently healthy individuals the renal clearance of amylase is less than 5% that of creatinine; in acute pancreatitis the ratio is said to be greater than 0.05 or 5%.
(05 Mar 2000)
aspect ratio <radiobiology> In toroidal geometry, the ratio of the major diameter (total width of the torus) to the minor diameter (width of a slice taken through one side of the ring). In inertial-confinement fusion, aspect ratio refers to the ratio of a fuel pellet's radius to its wall thickness.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • conversion ratio
    Àüȯ ºñÀ²(Çٺп­½Ã ÇϳªÀÇ ¿øÀÚ¿¡¼­ »ý±â´Â ¿øÀÚÀÇ ¼ö
  • cost performance (ratio)
    ºñ¿ë´ë ¼º´Éºñ
  • direct ratio
    (¼ö)Á¤ºñ;Á¤ºñ·Ê
  • elderly dependency ratio
    ³ë·ÉÀÚ(ÇÇ)ºÎ¾ç·ü
  • focal ratio
    =F-NUMBER
  • inverse ratio
    (¼ö)¹Ýºñ;¿ªºñ
  • mass ratio
    Áú·®ºñ (ÃßÁøºÎ¸¦ Á¦¿ÜÇÑ ·ÎÄÏ º»Ã¼¿¡ ´ëÇÑ ÃÑÁß·®ÀÇ ºñÀ²,ÃßÁø¾à ÃæÀüÀ²)
  • payout ratio
    ¹è´ç ¼ºÇâ
  • priceearnings ratio
    ÁÖ°¡ ¼öÀÍ·ü 9
  • ratio
    ºñ;ºñÀ²
  • respiratory quotient (ratio)
    È£Èí·ü;È£Èíºñ(³»¹ñ´Â ź»ê°¡½ºÀÇ ¾ç°ú ¿ÜºÎ·ÎºÎÅÍ Èí¼öÇÏ´Â »ê¼Ò·®°úÀÇ ºñ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á